# First Time in Human Study Using GSK2330672

> **NCT01416324** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 17 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** placebo
- **DRUG:** 0.1 mg GSK2330672
- **DRUG:** 0.3 mg GSK2330672
- **DRUG:** 1 mg GSK2330672
- **DRUG:** 3 mg GSK2330672
- **DRUG:** 10 mg GSK2330672
- **DRUG:** 30 mg GSK2330672
- **DRUG:** 60 mg GSK2330672

## Key facts

- **NCT ID:** NCT01416324
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06-15
- **Primary completion:** 2011-09-09
- **Final completion:** 2011-09-09
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2017-06-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01416324

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01416324, "First Time in Human Study Using GSK2330672". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01416324. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*